S
Samir K. Gupta
Researcher at Indiana University
Publications - 112
Citations - 4158
Samir K. Gupta is an academic researcher from Indiana University. The author has contributed to research in topics: Renal function & Kidney disease. The author has an hindex of 31, co-authored 112 publications receiving 3787 citations. Previous affiliations of Samir K. Gupta include University of Wisconsin-Madison & Vanderbilt University.
Papers
More filters
Journal ArticleDOI
Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America
Samir K. Gupta,Joseph A. Eustace,Jonathan A. Winston,Ivy I. Boydstun,Tejinder S. Ahuja,Rudolph A. Rodriguez,Karen T. Tashima,Michelle E. Roland,Nora Franceschini,Frank J. Palella,Jeffrey L. Lennox,Paul E. Klotman,Sharon Nachman,Stephen D. Hall,Lynda A. Szczech +14 more
TL;DR: This research presents a meta-analysis of the immune system’s response to Epstein-Barr virus, which has the potential to improve the quality of life of patients and reduce the likelihood of adverse events.
Journal ArticleDOI
The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection
Lynda A. Szczech,Samir K. Gupta,Ramez Habash,Antonio Guasch,Robert C. Kalayjian,Richard G. Appel,Timothy A. Fields,Laura P. Svetkey,Katherine H. Flanagan,Paul E. Klotman,Jonathan A. Winston +10 more
TL;DR: Among HIV-infected patients with renal disease other than HIVAN, viral suppression and the use of antiretroviral therapy are not associated with a beneficial effect on renal function; thus, additional therapeutic strategies may need to be utilized.
Journal ArticleDOI
Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America
Gregory M. Lucas,Michael W. Ross,Peter G. Stock,Michael G. Shlipak,Christina M. Wyatt,Samir K. Gupta,Mohamed G. Atta,Kara Wools-Kaloustian,Paul A. Pham,Leslie A. Bruggeman,Jeffrey L. Lennox,Patricio E. Ray,Robert C. Kalayjian +12 more
TL;DR: IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.
Journal ArticleDOI
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
Anton Pozniak,Jose R. Arribas,Joseph Gathe,Samir K. Gupta,Frank A. Post,Mark Bloch,Anchalee Avihingsanon,Gordon Crofoot,Paul M. Benson,Kenneth A. Lichtenstein,Moti Ramgopal,Ploenchan Chetchotisakd,Joseph M. Custodio,Michael E. Abram,Xuelian Wei,Andrew K. Cheng,Scott McCallister,Devi SenGupta,Marshall W. Fordyce +18 more
TL;DR: These data support the efficacy and safety of once daily E/C/F/TAF in HIV+ patients with mild or moderate renal impairment without dose adjustment and Proteinuria, albuminuria and bone mineral density significantly improved.
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
Anton Pozniak,Jose R. Arribas,Joseph Gathe,Samir K. Gupta,Frank A. Post,Mark Bloch,Anchalee Avihingsanon,Gordon Crofoot,Paul M. Benson,Kenneth A. Lichtenstein,Moti Ramgopal,Ploenchan Chetchotisakd,Joseph M. Custodio,Michael E. Abram,Xuelian Wei,Andrew K. Cheng,Scott McCallister,Devi SenGupta,Marshall W. Fordyce +18 more
TL;DR: In this article, the authors reported the 48 week safety and efficacy of a once-daily single tablet regimen of elvitegravir 150 mg (E), cobicistat 150 mg(C), emtricitabine 200 mg (F), and TAF 10 mg(E/C/F/TAF) in HIV-1-infected patients with mild to moderate renal impairment.